Kenneth R. Chien

Kenneth R. Chien is an American doctor and medical scientist who has been a research director at Karolinska Institute, in Stockholm, since 2013. Chien has several papers with over 1,000 citations and a h-index of 132. His area of expertise is cardiovascular science. His research into regenerative cardiovascular medicine, specifically while director of the Cardiovascular Program of the Harvard Stem Cell Institute, led to his co-founding, in 2013, of Moderna Therapeutics. In 2018, the company re-branded as Moderna, Inc. Chien is a recipient of the Walter Bradford Cannon Award of the American Physiology Society and the Pasarow Award. He is a member of the Norwegian Academy of Sciences, the Austrian Academy of Sciences, and has received an honorary doctorate from the University of Edinburgh.
Education.
Kenneth Chien earned a BA from Harvard College in Biology before earning his PhD and MD from Pennsylvania's Temple University. He continued to study internal medicine and cardiology at the University of Texas Southwestern Medical Center in Dallas. At Temple, Chien's PhD thesis was entitled "Biochemical events in irreversible, ischemic liver cell injury", which was published in 1982 and for which he conducted his dissertation in 1983.He is also a third generation Harvard alumnus, following his father and grandfather.
Career and research.
Chien became a member of the faculty at the University of California at San Diego, acting as director of the Institute for Molecular Medicine from 2000 to 2005, with an adjunct appointment as a Professor of the Salk Institute. During that period, Chien was also responsible for co-founding the Institute of Molecular Medicine at Beijing's Peking University. Chien then worked as Scientific Director of the Cardiovascular Research Center at Massachusetts General Hospital from 2005 to 2012, concurrent to directing the Cardiovascular Program of the Harvard Stem Cell Institute from 2007 to 2013. In 2013 Chien took up a position as Professor of Cardiovascular Research and Research Director or the Wallenberg-Cardiovascular Initiative at Karolinska Institute in Stockholm, Sweden. In an interview, Chien discussed the opportunity at KI to work closely with Astrazeneca in Molndal to move forward discoveries in regenerative therapeutics made in his lab towards clinical application, as well as praising Sweden as “a country that has decided to put its faith in science and technology". Dr. Chien has received numerous grants from the National Heart, Lung, And Blood Institute, dating back to 1985. He has also applied for several patents, securing a total of 17.
Moderna involvement.
While working at Harvard, Chien was approached by Derrick Rossi, a colleague at the Harvard Stem Cell Institute, about co-founding a newco, based on findings in the Rossi lab on reprogramming stem cells with mRNA. This eventually turned into the medical research company Moderna Therapeutics, co-founded by Rossi, Chien and Bob Langer under the aegis of Flagship VentureLabs in 2011. In 2011, the Chien Lab made the discovery of the high efficiency expression of VEGF mRNA in heart muscle, resulting in a patent on the discovery that triggered mRNA towards therapeutic applications. In 2013, Chien and his associates documented the ability of VEGF mRNA for coronary vascular regeneration and to reverse the onset of heart dysfunction, thereby opening the potential of were researching the possibility of using synthetic messenger RNA (mRNA) to produce therapeutic desired effects in a patient's muscle cells:
"“What we have shown is that muscle cells take up this synthetic mRNA and will express almost any protein quickly. The technology will allow an intense, focused, one‐time application to drive a therapeutic effect that might have a long‐lasting effect by affecting, expanding and redirecting the fate of rare native tissue progenitors that are normally mobilized during injury and usually contribute to scar tissue.”" 
At Karolinska, the Chien lab documented the ability to generate large numbers of human Islet heart progenitor cells from human embryonic stem cells, which resulted in a partnership with Astrazeneca to move the project toward clinical application.
In February 2019, AstraZeneca and the Chien lab reported the first in human study of an mRNA therapeutic, noting reversal of vascular dysfunction in diabetic patients by VEGF mRNA.